Significance of the hydrophobic residues 225 to 230 of apoA-I for the biogenesis of HDL

Panagiotis Fotakis§†, Ioanna Tiniakou‡, Andreas K. Kateifides§†, Christina Gkolfinopoulou‡, Angeliki Chroni‡, Efstratios Stratikos‡, Vassilis I. Zannis§†**, Dimitris Kardassis†^*

§Molecular Genetics, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118; †Department of Biochemistry, University of Crete Medical School, Heraklion, Crete, Greece 71110; ‡National Center for Scientific Research "Demokritos", Athens, Greece 15310

*To whom correspondence should be addressed. T: 617-638-5085; F: 617-638-5141; E: vzannis@bu.edu

^Equal contribution of the two collaborators

Running Title: Role of the 225-230 region of apoA-I in HDL biogenesis

Key Words: apolipoprotein A-I mutations; HDL biogenesis; pre β and α HDL particles; dyslipidemia; LCAT
ABSTRACT

We have studied the significance of four hydrophobic residues within the 225-230 region of apoA-I on its structure and functions and their contribution to the biogenesis of HDL. Adenovirus-mediated gene transfer of an apoA-I[F225A/V227A/F229A/L230A] mutant in apoA-I\(^{-/-}\) mice decreased plasma cholesterol, HDL cholesterol and apoA-I levels. When expressed in apoA-I\(^{-/-}\) x apoE\(^{-/-}\) mice, approximately 40% of the mutant apoA-I as well as mouse apoA-IV and apoB-48 appear in the VLDL/IDL/LDL. In both mouse models the apoA-I mutant generated small spherical particles of pre\(\beta\) and \(\alpha_4\) HDL mobility. Co-expression of the apoA-I mutant and human lecithin: cholesterol acyltransferase (LCAT) increased and shifted the HDL cholesterol peak towards lower densities, created normal \(\alpha\)HDL subpopulations and generated spherical HDL particles. Biophysical analyses suggested that the apoA-I[225-230] mutations led to a more compact folding that may limit the conformational flexibility of the protein. The mutations also reduced the ability of apoA-I to promote ABCA1 mediated-cholesterol efflux and to activate LCAT to 31% and 66% respectively of the WT control. Overall, the apoA-I[225-230] mutations inhibited the biogenesis of HDL and led to the accumulation of immature pre\(\beta\) and \(\alpha_4\) HDL particles, a phenotype that could be corrected by administration of LCAT.
INTRODUCTION

Previous studies by us showed the overall importance of the 220-231 region of apoA-I for apoA-I/ABCA1 interactions and the biogenesis of HDL but did not identify the apoA-I residues involved (1;2). Other studies also showed the importance of the C-terminal region for the structure of apoA-I (3-5) as well as for other functions of apoA-I (6;7). In the preceding publication we have investigated the role of the hydrophobic residues L218, L219, V221, L222 and the charged residues E223, K226 on the structure and functions of apoA-I and their contribution to the biogenesis of HDL (8). These studies showed that substitution of the hydrophobic residues L218, L219, V221, L222 of apoA-I by Alanines inhibits the biogenesis and maturation of HDL and generates a phenotype that cannot be corrected by LCAT. Expression of E223, K226 caused lesser but discrete alterations in the HDL phenotype.

The rationale for the present study was that the 225-230 region of apoA-I contains four additional hydrophobic residues that may be equally significant for its structure and functions. For this reason we have used gene transfer in two mouse models, biochemical and biophysical analyses to study the impact of substitutions of residues F225, V227, F229, L230 by Alanines on the structure and functions of apoA-I and their impact on the biogenesis of HDL. In vitro experiments showed that the apoA-I[225-230] mutations affected the structure of apoA-I, diminished its capacity to promote ABCA1-mediated cholesterol efflux and decreased moderately its ability to activate LCAT. Gene transfer of the apoA-I mutant in apoA-I−/− and apoA-I−/− x apoE−/− mice resulted in the reduction of plasma apoA-I and HDL levels and led to the formation of spherical particles with preβ and α4 HDL electrophoretic mobility. In contrast to the apoA-I[218-222] mutant described in the preceding article (8) the defective HDL phenotype, caused by the 225-230 mutations, could be corrected by co-expression of the apoA-I mutant and human LCAT.
EXPERIMENTAL PROCEDURES

Materials

Materials not mentioned in the experimental procedures have been obtained from sources described previously (9;10).

Methods

**Generation of adenoviruses expressing the wild-type (WT) and the mutant apoA-I forms.** The apoA-I gene lacking the BglII restriction site that is present at nucleotide position 181 of the genomic sequence relative to the ATG codon of the gene, was cloned into the pCDNA3.1 vector to generate the pCDNA3.1-apoA-I(ΔBglII) plasmid as described (11). This plasmid was used as a template to introduce the apoA-I mutations F225A/V227A/F229A/L230A using the QuickChange® XL mutagenesis kit (Stratagene, Santa Clara, CA) and the mutagenic primers shown in supplemental Table 1. The recombinant viruses were constructed using the Ad-Easy-1 system where the recombinant adenovirus construct is generated in bacteria BJ-5183 (purchased from Stratagene) (12). The recombinant adenoviruses were packaged in 911 cells, amplified in human embryonic kidney 293 (HEK 293) cells, purified and titrated as described (11).

*ApoA-I production, purification, ABCA1-dependent cholesterol efflux and LCAT assays, Physicochemical measurements, Animal studies and Statistics have been described in the preceding article (8).*
RESULTS

Secretion of the WT and the apoA-I[225-230] mutant in the culture media of cells. The secretion of WT and mutant form of apoA-I in the culture medium of HTB-13 cells expressing the WT and the mutant apoA-I form was assessed by SDS-PAGE analysis of the culture media. As shown in supplemental Figure 1, both the WT and the apoA-I[225-230] mutant were secreted at comparable levels in the culture medium of the apoA-I-expressing cells.

Expression of the apoA-I transgenes following adenovirus infection. Total hepatic RNA was isolated from the livers of apoA-I−/− or apoA-I−/− x apoE−/− mice four days post infection with adenoviruses expressing the WT apoA-I and the apoA-I[225-230] mutant. qRT-PCR analysis of the apoA-I mRNA levels showed that the expression of the apoA-I[225-230] mutant was comparable to WT apoA-I in apoA-I−/− x apoE−/− mice but slightly elevated in apoA-I−/− mice (Table 1 A, B).

Plasma lipid and apoA-I levels and FPLC profiles. Plasma lipids and apoA-I levels were determined four days post infection of apoA-I−/− or apoA-I−/− x apoE−/− mice with adenoviruses expressing the WT and the mutant apoA-I form. It was found that in apoA-I−/− mice the apoA-I[225-230] mutant decreased plasma cholesterol and apoA-I levels to 23% and 34% respectively as compared to WT apoA-I. Plasma triglycerides were not affected by the apoA-I mutations (Table 1 A). FPLC analysis of plasma from apoA-I−/− mice infected with the recombinant adenovirus expressing either WT apoA-I or the apoA-I[225-230] mutant showed that all the cholesterol was distributed in the HDL region and the HDL cholesterol peak of the apoA-I[225-230] mutant was greatly diminished (Figure 1 A).

Fractionation of plasma of apoA-I−/− mice expressing the WT apoA-I or the apoA-I[225-230] mutant, EM analysis and two dimensional electrophoresis. Fractionation of plasma by density gradient ultracentrifugation and subsequent analysis of the resulting fractions by SDS-PAGE showed that both the WT apoA-I and the apoA-I[225-230] mutant were predominantly distributed in the HDL3 region and to a lesser extend in the HDL2 region (Figure 1 B, C). Compared to WT apoA-I, the quantity of the apoA-I[225-
230] mutant was greatly reduced (Figure 1 B, C). Flotation of other apolipoproteins in the VLDL/LDL/IDL/HDL region was not observed when the WT apoA-I and the apoA-I[225-230] mutant were expressed in apoA-I/-/ mice.

Analysis of the HDL fractions 6 and 7 obtained following density gradient ultracentrifugation by EM, showed that both the WT apoA-I and the apoA-I[225-230] mutant generated spherical particles (Figure 1 D, E). The diameter of the particles were 10±1.7 nm for the WT apoA-I and 8±1.3 for the apoA-I[225-230] mutant. Two-dimensional gel electrophoresis of plasma showed that WT apoA-I formed normal preβ and α1, α2, α3, α4-HDL subpopulations (Figure 1 F) whereas the apoA-I[225-230] mutant formed predominantly preβ and α4 subpopulations (Figure 1 G).

To assess how apoE deficiency affects HDL biogenesis, we also performed gene transfer experiments in apoA-I−/− x apoE−/− mice, which lack both apoA-I and apoE. The plasma cholesterol and triglyceride levels of mice expressing the apoA-I[225-230] mutant were comparable to those of the non-infected apoA-I−/− x apoE−/− mice (Table 1 B). In contrast, the plasma cholesterol levels of the mice expressing the WT apoA-I was increased 1.5-fold as compared to the apoA-I−/− x apoE−/− mice and the mice developed hypertriglyceridemia. The difference in the plasma cholesterol levels between apoA-I−/− x apoE−/− mice expressing WT apoA-I and the apoA-I[225-230] mutant can be explained by the corresponding FPLC analyses of the plasmas. This analysis showed that in apoA-I−/− x apoE−/− mice expressing the WT apoA-I, approximately two thirds of the cholesterol is found in the VLDL/IDL region and the remaining in the HDL region. In contrast, in mice expressing the apoA-I[225-230] mutant the great majority of the cholesterol (>90%) is found in the VLDL/IDL region and the remaining in the LDL region. There is no appreciable HDL cholesterol peak in the HDL region (Figure 2 A). All triglycerides are found in the VLDL/IDL region (Figure 2 B).

Fractionation of the plasma by density gradient ultracentrifugation showed that WT apoA-I was distributed predominantly in the HDL2/HDL3 region with small amounts in the VLDL/IDL/LDL region.
(Figure 2 C). Similar analysis for the apoA-I[225-230] mutant showed that apoA-I and mouse apoA-IV are distributed in all lipoprotein fractions and the VLDL/IDL/LDL/HDL2 fractions were enriched with mouse apoB-48 (Figure 2 D). EM analysis of the fractions 6 & 7 obtained by density gradient ultracentrifugation of the plasma showed that both the WT apoA-I and the apoA-I mutant generated spherical particles that differed in size (Figure 2 E, F). The diameter of the particles were 9.2±1.9 nm for the WT apoA-I and 7±2.3 for the apoA-I[225-230] mutant. Larger spherical particles corresponding in size to IDL and LDL were observed in the HDL density fractions of apoA-I<sup>-/-</sup>x apoE<sup>-/-</sup> mice expressing the apoA-I[225-230] mutant. The appearance of the IDL and LDL size particles coincides with the presence of apoB-48 in fractions 6 & 7 used for the EM analysis (Figure 2 D). Two dimensional gel electrophoresis showed that the plasma of mice expressing WT apoA-I contained the normal preβ and αHDL subpopulations (Figure 2 G), whereas the plasma of mice expressing the apoA-I[F225A/V227A/F229A/L230A] mutant contained predominantly (~70%) preβ, smaller amounts of (~30%) of α4 HDL and few α3 HDL particles (Figure 2 H). The relative migration of the particles generated by WT apoA-I and the apoA-I[225-230] mutant in apoA-I<sup>-/-</sup> and apoA-I<sup>-/-</sup>x apoE<sup>-/-</sup> mice were established by two dimensional gel electrophoresis of mixtures of the plasmas containing these two apoA-I forms (supplemental Figure 2 A, B).

To assess whether the defective phenotype of the apoA-I[225-230] mutant can be corrected by LCAT we carried out gene transfer of both the apoA-I[225-230] mutant and LCAT in apoA-I<sup>-/-</sup> and apoA-I<sup>-/-</sup>x apoE<sup>-/-</sup> mice. In apoA-I<sup>-/-</sup> the co-expression of the apoA-I[225-230] mutant and LCAT increased plasma cholesterol without changing the plasma triglyceride levels (Table 1 A). The FPLC analysis of the plasma showed that the increase in plasma cholesterol was accompanied by a dramatic increase in the HDL cholesterol peak and its shift towards the lower densities (Figure 3 A). In double deficient mice the co-expression of the apoA-I[225-230] mutant with LCAT caused a 2.3-fold increase in plasma cholesterol, as compared to non-infected mice, without any significant change in plasma triglycerides (Table 1 B). The FPLC analysis showed that the increase in plasma cholesterol was associated with the generation of
a cholesterol shoulder that extended from VLDL to HDL (Figure 3 B). Density gradient ultracentrifugation of plasma in apoa-I⁻/⁻ mice co-expressing the apoa-I[225-230] mutant and LCAT showed that the major proportion of apoa-I was distributed mainly in the HDL2 region and a smaller amount in the VLDL/IDL/LDL and HDL3 regions. Mouse apoE was distributed predominantly in the VLDL/IDL/LDL region and to a lesser extend in the HDL2 region. Apoa-IV floated in all lipoprotein fractions (Figure 3 C). The identity of the apoa-IV and apoE bands was confirmed by western blotting (data not shown). In apoa-I⁻/⁻ x apoE⁻/⁻ mice expressing both the apoa-I[225-230] mutant and LCAT, both apoa-I and apoa-IV were distributed in all lipoprotein fractions. ApoB-48 was present predominantly in the VLDL/IDL/LDL and HDL2 region and to a lesser extent in the HDL3 region (Figure 3 D). Electron microscopy of the HDL fractions 6 and 7 obtained from the plasma of apoa-I⁻/⁻ mice co-expressing the apoa-I[225-230] mutant and LCAT showed the presence of spherical particles of 11±3.1 nm diameter (Figure 3 E). Similar analysis of the HDL fractions 6 and 7 of plasma of apoa-I⁻/⁻ x apoE⁻/⁻ mice co-expressing the apoa-I[225-230] mutant and LCAT also showed the presence of spherical particles of 10.3±2.8 nm diameter as well as a greater proportion of the larger particles that correspond in size to VLDL/IDL/LDL size (Figure 3 F). Two-dimensional gel electrophoresis of plasma of both apoa-I⁻/⁻ and apoa-I⁻/⁻ x apoE⁻/⁻ mice showed that the co-expression of the apoa-I[225-230] mutant with LCAT restored the normal preβ and αHDL subpopulations and generated αHDL size subpopulations with larger size (Figure 3 G, H).

**Comparative analysis of the in vitro functions and physicochemical properties of the WT apoa-I and the apoa-I[225-230] mutant.** The WT apoa-I and the apoa-I[225-230] mutant were purified from the culture media of HTB-13 cells expressing the corresponding proteins and used for in vitro functional and physicochemical studies. The functional studies showed that the ability of this mutant to promote ABCA1-mediated cholesterol efflux and to activate LCAT was 31% and 66% respectively as compared to the WT control (Figure 4 A, B).
Circular dichroism measurements indicated 7.6% loss of helical content in the apoA-I[225-230] mutant (Table 2 and supplemental Figure 3 A). Thermal unfolding followed by the CD signal showed that the F225A/V227A/F229A/L230A mutations caused a more cooperative unfolding transition as compared to WT apoA-I (Table 2 and supplemental Figure 3 B). In contrast, the chemical unfolding profile of the mutant, probed by the intrinsic tryptophan fluorescence, was similar to that of the wild-type apoA-I (Table 2 and supplemental Figure 3 C). Finally, the ANS fluorescence measurements show that the F225A/V227A/F229A/L230A mutations caused a 41% reduction of hydrophobic surface exposure to the solvent (Table 2 and supplemental Figure 3 D).

DISCUSSION

The F225A/V227A/F229A/L230A mutations alter the functional and physicochemical properties of apoA-I. The functional assays probed two well characterized properties of lipid free and lipoprotein bound apoA-I, which are its ability to promote ABCA1 mediated cholesterol efflux and to activate LCAT respectively (1;13;14). The decreased capacity of the apoA-I[225-230] mutant to promote ABCA1 mediated cholesterol efflux (31% of the WT control) is expected to influence its capacity to form HDL in vivo. The reduction in the ability of the apoA-I mutant to activate LCAT was modest (65% of WT control). However, previous studies showed that the capacity of reconstituted HDL containing an apoA-I mutant to activate LCAT in vitro does not always predict their ability to affect LCAT activation in vivo (15;16).

The physicochemical analysis of the apoA-I[225-230] mutant suggested that the mutations lead to a more compact folding that may limit the conformational flexibility of the protein. The observed 7.6% decrease in the protein’s α-helical content indicates that the structural changes brought about by the mutations extend beyond the limited area of the location of the mutations. Thermodynamic stability analysis indicated that the mutation also resulted to a protein that is thermodynamically stabilized and
presents a more cooperative unfolding transition and compact structure. This was only evident during thermal unfolding and not during chemical denaturation. Since, however, the chemical denaturation reports only on the local environment of the tryptophan residues of the protein, which are all located on the N-terminal region of ApoA-I, this observation suggests that the structural repercussions brought about by the mutations may be limited to the C-terminal region of apoA-I where the mutation resides. In either case, a more cooperative thermal transition signifies a more compact structure with reduced conformational flexibility, a property that is necessary for lipid association. A recent related study involving different amino acid substitutions within the 225-236 region of apoA-I explored the effects of the aromatic and hydrophobic residues F225, F229, A232 and Y236 on the cholesterol efflux capacity and the ability of apoA-I to solubilize phospholipids and form HDL particles by cell cultures. It was concluded that both functions were similar to those of WT apoA-I when the overall hydrophobicity of apoA-I was not affected by the mutations in residues F225, F229, A232 and Y236. However both functions were impeded by a factor of three by substitution of the aromatic amino acids that decreased the hydrophobicity of apoA-I (17). Another important finding of the present study is that although F225/V227/F229/L230 represent ~5% of total hydrophobic amino acids of apoA-I, their substitution by Alanines resulted in a 41% reduction in the ANA fluorescence, indicating that these residues constitute a major solvent-exposed hydrophobic patch on the surface of apoA-I. Overall, our findings suggest that the F225A/V227A/F229A/L230A mutations greatly affect the structural integrity and conformational flexibility of apoA-I, effects that may at least partially underlie the observed changes in its \textit{in vitro} and \textit{in vivo} functions.

The 225-230 mutations are associated with abnormalities in the biogenesis and maturation of HDL. In previous studies, systematic mutagenesis and gene transfer of human apoA-I mutants in apoA-I deficient mice disrupted specific steps along the pathway of the biogenesis of HDL and generated discrete HDL phenotypes (16). These phenotypes were characterized by low HDL levels, preponderance
of immature HDL subpopulations or accumulation of discoidal HDL particles in plasma (1;10;11;15;18;19).

To obtain a clearer picture how the apoA-I mutations affected different steps of the biogenesis and maturation of HDL in the presence or the absence of the endogenous mouse apoE, the gene transfer studies were carried out in apoA-I−/− mice that lack mouse apoA-I and the apoA-I−/− x apoE−/− mice that lack both mouse apoA-I and apoE.

The studies in apoA-I−/− mice showed that the expression of the apoA-I[225-230] mutant was associated with great reduction in the plasma cholesterol and apoA-I levels despite the fact that the expression of the mutant transgene was higher than that of the WT apoA-I transgene. The reduction in plasma apoA-I was associated with a great decrease in the HDL cholesterol levels as determined by FPLC fractionation of the plasma and was further confirmed by density gradient ultracentrifugation of plasma which showed reduction in the quantity of the apoA-I[225-230] mutant.

Potential abnormalities in the HDL phenotype in apoA-I−/− mice, resulting from the expression of the apoA-I[225-230] mutant, were verified by two-dimensional gel electrophoresis of plasma that showed the formation of preβ and α4 HDL particles. Accumulation of such particles is indicative of defective maturation of HDL due to insufficiency of mouse LCAT (11;18). The LCAT insufficiency may originate from fast catabolism of the nascent HDL particles along with the endogenous LCAT bound to them (11). Fast catabolism of the nascent HDL particles by the kidney has been described previously (18;20).

The plasma of both of apoA-I−/− and apoA-I−/− x apoE−/− mice expressing the apoA-I[225-230] mutant contained predominantly preβ and to a lesser extent α4 HDL particles; thus reaffirming the concept that the apoA-I[225-230] mutations affected the biogenesis of HDL. An unexpected finding was that the expression of the apoA-I[225-230] mutant in apoA-I−/− x apoE−/− mice resulted in the flotation of the mutant protein in all density fractions, along with mouse apoA-IV and apoB-48. The presence of
apoB-48 in the higher density fractions affected the particle composition of the HDL fraction, by enriching it with larger particles corresponding in size to VLDL, IDL and LDL. Previous studies showed that apoA-IV can also generate apoA-IV containing HDL particles (21). It is thus possible that apoA-IV containing HDL may fuse with apoB-48 containing particles and pull them towards the higher density regions.

**LCAT corrects the aberrant HDL phenotype caused by the apoA-I[225-230] mutations.** In previous studies we have shown that naturally occurring or bioengineered point mutations in apoA-I when expressed in mouse models, activate LCAT insufficiently and in some instances may lead to the accumulation of discoidal HDL particles in plasma (18;19). Other mutations lead to very low levels of HDL cholesterol levels and accumulation of premature preβ and α4 HDL particles in plasma (11). A characteristic feature of these mutations is that the low HDL levels and the abnormal HDL phenotype could be corrected in vivo by gene transfer of LCAT (11;18;19). The preceding article showed that substitutions of residues L218, L219, V221, L222 by Alanines led to the generation of a unique and previously undetected low HDL phenotype that was characterized by the formation of only preβ HDL particles and could not be converted to spherical particles by excess LCAT (8). Since the changes in the structure and the functions of the apoA-I[225-230] and the apoA-I[218-222] mutant had several similarities, we carried out experiments to determine whether the aberrant HDL phenotype generated by the apoA-I[225-230] mutations could be corrected by LCAT. These experiments showed that co-expression of the LCAT and the apoA-I[225-230] mutant in apoA-I−/− mice restored the HDL cholesterol peak of the FPLC profile and shifted it towards lower densities (Compare Figure 1 A with Figure 3 A). It also increased apoA-I levels and shifted its distribution to lower densities (compare Figure 1 B with Figure 3 C). Finally, it promoted the appearance of mouse apoE predominantly in the lower densities and of apoA-IV in all lipoprotein fractions (compare Figure 1 B with Figure 3 C).
Similar experiments in double deficient mice, showed that the co-expression of the LCAT and the apoA-I[225-230] mutant created a cholesterol shoulder that extended from VLDL to HDL as determined by FPLC analysis (Figure 3 B). The distribution of the mutant apoA-I, apoA-IV and apoB-48 in different densities was similar to that observed in mice expressing the apoA-I mutant alone (Figure 3 D). In both mouse models the LCAT treatment created normal preβ and αHDL subpopulations and generated spherical HDL particles of larger size. Thus, the observed LCAT insufficiency caused by the apoA-I[225-230] mutations could be reversed by treatment with LCAT.

The ability of LCAT to restore aberrant HDL phenotype caused by genetic or environmental factors may have important clinical implications for the correction of HDL abnormalities in humans. An abnormality that persisted in apoA-I−/− x apoE−/− mice expressing the apoA-I[225-230] mutant was the presence of VLDL, IDL and LDL size particles in the HDL fractions.

The present study in combination with the preceding study (8) shows the essential role of eight hydrophobic residues present in the 218-230 region of apoA-I for the structure and functions of apoA-I and its ability to form HDL. The two studies enhance our understanding of the complex factors that contribute to the correct extracellular assembly, maturation and proteomic composition of HDL. Future studies are required to identify by existing and new assays how the aberrant forms of HDL identified in these and previous studies (1;2;10;11;15;18;19) affect different functions of HDL that are required for protection from atherosclerosis and other diseases.
REFERENCES


**Acknowledgments**: Panagiotis Fotakis, Ioanna Tiniakou and Andreas Kateifides are students of the graduate program “The Molecular Basis of Human Disease” of the University of Crete Medical School. We thank Gayle Forbes for technical assistance.

**Sources of Funding**: This work was supported by a grant from the National Institutes of Health HL48739, by the General Secretariat of Research and Technology of Greece (Synergasia 09SYN-12-897 to D.K and A.C) and by and the Ministry of Education of Greece (Thalis MIS 377286 to D.K., A.C., and E.S.). P. Fotakis has been supported by pre-doctoral training Fellowship HERAKLEITOS II of the Greek Ministry of National Education.

**Disclosures**: There are no conflicts to report.

**Abbreviations**: The abbreviations used are: ABCA1, ATP-binding cassette transporter A1; ANS, 8-anilino-1-naphthalene-sulfonate; apoA-I, apolipoprotein A-I; apoA-I<sup>–1/–</sup>, apoA-I-deficient; BSA, bovine serum albumin; CD, circular dichroism; DMPC, dimyristoyl-L-α-phosphatidylcholine; EM, electron microscopy; GdnHCl, guanidine hydrochloride; HEK293, human embryonic kidney 293; HTB-13, SW 1783 human astrocytoma; POPC, β-oleoyl-γ-palmitoyl-L-α-phosphatidylcholine; WMF, wavelength of maximum fluorescence; WT, wild-type.
Table 1: Plasma lipids, apoA-I and hepatic mRNA levels of apoA-I^-/- (A) or apoA-I^-/- x apoE^-/- (B) mice expressing wild type (WT) and the mutant form of apoA-I as indicated.

A.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>apoA-Ih mRNA levels (%)</td>
<td>Non detectable</td>
<td>100 ± 15*</td>
<td>130 ± 10*</td>
</tr>
<tr>
<td>Plasma apoA-Ih protein (mg/dL)</td>
<td>Non detectable</td>
<td>173±63</td>
<td>59±17±</td>
</tr>
<tr>
<td>Plasma cholesterol (mg/dL)</td>
<td>27 ± 8</td>
<td>182 ± 82^</td>
<td>41 ± 12%^</td>
</tr>
<tr>
<td>Plasma triglycerides (mg/dL)</td>
<td>34 ± 14</td>
<td>39 ± 15</td>
<td>42 ± 14</td>
</tr>
</tbody>
</table>

B.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>apoA-Ih mRNA levels (%)</td>
<td>Non detectable</td>
<td>100 ± 21*</td>
<td>140 ± 50</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>337 ± 107</td>
<td>520 ± 85</td>
<td>377 ± 90</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>58 ± 23</td>
<td>680 ± 290^</td>
<td>35 ± 22§</td>
</tr>
</tbody>
</table>

Values are means ± standard deviation based on analysis of 5-8 mice per experiment.

(*) Expression of WT apoA-I in the apoA-I^-/- or apoA-I^-/- x apoE^-/- was set to 100%. Expression of LCAT was also confirmed by RT-PCR. Statistical significant differences at p<0.05 were calculated between untreated mice and mice expressing the WT apoA-I and the apoA-I-[F225A/V227A/F229A/L230A] in either the apoA-I^-/- or apoA-I^-/- x apoE^-/- mouse background and are indicated as follows: (†) p≤0.05 relative to WT apoA-I control. (‡) p≤0.05 relative to WT apoA-I control. (¶) p≤0.05 relative to untreated control. (‖) p≤0.05 relative to WT apoA-I control.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Helicity*</th>
<th>Thermal Denaturation*</th>
<th>Chemical Denaturation*</th>
<th>ANS binding*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>α-helix</td>
<td>Tm (°C)</td>
<td>Slope*</td>
<td>Coop</td>
</tr>
<tr>
<td>apoA-I</td>
<td></td>
<td></td>
<td></td>
<td>index (n)</td>
</tr>
<tr>
<td>WT</td>
<td>59.3±0.5</td>
<td>56.0±0.5</td>
<td>7.8±0.1</td>
<td>6.3±0.4</td>
</tr>
<tr>
<td>F225A/V227A/F229A/L230A</td>
<td>51.7±0.31</td>
<td>57.8±0.2</td>
<td>4.0±0.01</td>
<td>11.4±0.4</td>
</tr>
</tbody>
</table>

Values are means ± SD from three to four experiments.

1 p<0.0001; 2 p<0.05; 3 p<0.001; # Fold-increase in signal compared to unbound ANS.

* Slope is calculated from the fit of thermal denaturation curve to a Boltzman sigmoidal model curve using the equation [\Theta]_{222} = Bottom + ((Top-Bottom)/(1 =exp((Tm-X)/Slope))). X describes the temperature and slope describes the steepness of the curve, with a larger value denoting a shallow curve.

* Parameters obtained from the indicated measurements are as follows: α-helix, is the % α-helical content of the protein as calculated from the molecular ellipticity of the protein sample at 222nm. T_m, is middle point of the thermal denaturation transition (melting temperature). Slope, is the calculated slope of the linear component of the thermal denaturation transition, around the melting temperature. The cooperativity index n, is an indicator of the cooperativity of the thermal unfolding transition and is calculated using the Hill equation the Hill equation n=(log 81)/log(T_{0.9} /T_{0.1}), where T_{0.9} and T_{0.1} are the temperatures where the unfolding transition has reached a fractional completion of 0.9 and 0.1. D_{1/2} is the Guanidine HCl concentration at which the mid-point of the chemical denaturation is achieved. Fold-increase is the increase in ANS fluorescence in the presence of the protein relative to free ANS in the same buffer.
Figure Legends:

**Figure 1 (A-G):** Analysis of plasma of apoA-I⁻/⁻ mice infected with adenoviruses expressing the WT apoA-I or apoA-I[225-230] by FPLC (A) and by density gradient ultracentrifugation and SDS-PAGE (B, C). EM analysis of HDL fractions 6-7 obtained from apoA-I⁻/⁻ mice expressing the WT apoA-I (D) or apoA-I[225-230] mutant (E) following density gradient ultracentrifugation of plasma as indicated. The photomicrographs in this as well as in figures 2 and 3 were taken at 75,000× magnification and enlarged 3 times. The average diameter of the particles in this as well as in figures 2 and 3 was determined by measuring the diameter of 200 individual particles. Two dimensional gel electrophoresis of plasma of apoA-I⁻/⁻ mice infected with adenoviruses expressing WT apoA-I (F) or apoA-I[225-230] mutant (G).

**Figure 2 (A-H):** Analysis of plasma of apoA-I⁻/⁻ x apoE⁻/⁻ mice infected with adenoviruses expressing the WT apoA-I or apoA-I[225-230] mutant by FPLC (A, B) and by density gradient ultracentrifugation and SDS-PAGE (C, D). EM analysis of HDL fractions 6-7 obtained from apoA-I⁻/⁻ x apoE⁻/⁻ mice expressing the WT apoA-I (E) or apoA-I[225-230] mutant (F) following density gradient ultracentrifugation of plasma as indicated. Two dimensional gel electrophoresis of plasma of apoA-I⁻/⁻ x apoE⁻/⁻ mice infected with adenoviruses expressing WT apoA-I (G) or apoA-I[225-230] mutant (H).

**Figure 3 (A-H):** Analyses of plasma of apoA-I⁻/⁻ (A,C,E,G) or apoA-I⁻/⁻ x apoE⁻/⁻ mice (B,D,F,H) infected with adenoviruses expressing the apoA-I[225-230] mutant in combination with human LCAT. Plasma FPLC profiles of apoA-I[225-230] mutant alone or the apoA-I[225-230] mutant in combination with human LCAT in apoA-I⁻/⁻ (A) or apoA-I⁻/⁻ x apoE⁻/⁻ mice (B). SDS-PAGE of fractions obtained by density gradient ultracentrifugation from apoA-I⁻/⁻ (C) or apoA-I⁻/⁻ x apoE⁻/⁻ mice (D) mice.
expressing the apoA-I[225-230] mutant and human LCAT. EM analysis of HDL fractions 6-7 obtained from apoA-I<sup>-/-</sup> (E) or apoA-I<sup>-/-</sup> x apoE<sup>-/-</sup> (F) mice expressing the apoA-I[225-230] mutant and human LCAT following density gradient ultracentrifugation of plasma as indicated. Two dimensional gel electrophoresis of plasma of apoA-I<sup>-/-</sup> (G) or apoA-I<sup>-/-</sup> x apoE<sup>-/-</sup> (H) mice expressing the apoA-I[225-230] mutant and human LCAT.

**Figure 4 (A-B):** ABCA1-mediated cholesterol efflux from J774 mouse macrophages treated with cpt-cAMP using WT apoA-I and the apoA-I[225-230] mutant as cholesterol acceptors (A). LCAT activation capacity of WT apoA-I and the apoA-I[225-230] mutant. Experiments were performed as described in the experimental procedures. The data represent the average from two independent experiments performed in triplicate (B).
Figure 1

(A) Graph showing cholesterol levels in VLDL, LDL, and HDL.

(B) Gel electrophoresis showing WT apoA-I and apoA-I[p225-230].

(C) Gel electrophoresis showing apoA-I and apoA-I[p225-230] migration patterns.

(D) WT apoA-I HDL particle size: 10±1.7 nm.


(F) Western blot showing Preβ HDL and α-HDL.

(G) Western blot showing Preβ HDL and α-HDL for apoA-I[p225-230].
Figure 3

A

B

C

D

E

apoA-I(225-230) + LCAT in apoA-I/−/− mice

HDL particle size: 11±3.1 nm

F

apoA-I(225-230) + LCAT in apoA-I/− × apoE/− mice

HDL particle size: 10.3±2.8 nm

G

H

Preβ HDL
Figure 4

A

[4C]-Cholesterol efflux (% of total cholesterol)

14

12

10

8

6

4

2

0

WT apoA-I

apoA-I[F225A/V227A/F229A/L230A]

100%

31%

B

LCAT activation (V_{max app}/K_{m app})

6

5

4

3

2

1

0

WT apoA-I

apoA-I[F225A/V227A/F229A/L230A]

100%

66%

K_{m app} (μM) 0.57±0.17 0.16±0.07
V_{max app} (nmol CE/h) 2.40±0.08 0.45±0.17